Walleye Capital
IMVT icon

Walleye Capital’s Immunovant IMVT Stock Holding History

Walleye Capital’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$67.8K Buy
2,731
+2,730
+273,000% +$70.7K ﹤0.01% 3810
2025
Q4 		$25 Buy
+1
New +$22 ﹤0.01% 4458
2024
Q2 		– Sell
-15,534
Closed -$502K – 5784
2024
Q1 		$502K Buy
15,534
+10,639
+217% +$388K ﹤0.01% 3192
2023
Q4 		$206K Sell
4,895
-25,567
-84% -$941K ﹤0.01% 3656
2023
Q3 		$1.17M Buy
+30,462
New +$689K ﹤0.01% 2144
2023
Q1 		– Sell
-533,840
Closed -$9.48M – 4141
2022
Q4 		$9.48M Buy
533,840
+366,270
+219% +$4.61M 0.17% 133
2022
Q3 		$935K Buy
+167,570
New +$819K 0.02% 1029
2022
Q1 		– Sell
-32,956
Closed -$281K – 2422
2021
Q4 		$281K Buy
32,956
+17,121
+108% +$141K 0.01% 1286
2021
Q3 		$138 Sell
15,835
-19,310
-55% -$174K ﹤0.01% 1263
2021
Q2 		$371 Sell
35,145
-4,741
-12% -$66.2K 0.01% 866
2021
Q1 		$640 Buy
+39,886
New +$1.05M 0.04% 476

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Walleye Capital's IMVT Position: Q1 2026 in Review

Walleye Capital increased its Immunovant (IMVT) stake by 273,000% in Q1 2026, buying an estimated $70.7K and bringing the position to 2,731 shares worth $67.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3810.

Walleye Capital first reported a position in IMVT in Q1 2021 and has held it in 11 quarters since. The position peaked at $9.48M in Q4 2022. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

  • Walleye Capital held 2,731 shares of Immunovant worth $67.8K as of Q1 2026.
  • Walleye Capital bought 2,730 Immunovant shares in Q1 2026, an estimated $70.7K.
  • Immunovant made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #3810 holding.
  • Walleye Capital first reported a position in Immunovant in Q1 2021 and has held it in 11 quarters since.
  • Walleye Capital's Immunovant position peaked at $9.48M in Q4 2022.
  • 215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.